3.2.4. IBDQ
REMISSION
At week 10, filgotinib 200 mg-treated patients had a greater LS mean increase from induction baseline in IBDQ total score than placebo-treated patients (biologic-naïve: 51 vs 30 points, Δ 21 [95% CI, 13, 28], At week 58, patients in the filgotinib 200 mg group experienced an LS mean increase from maintenance baseline in IBDQ total score of 5 points, compared with a 9-point decrease in patients in the respective placebo group [IBDQ remission was achieved by greater proportions of filgotinib 200 mg-treated than placebo-treated patients at week 10 [biologic-naïve, 55.9% vs 35.0%; biologic-experienced, 43.1% vs 17.6%; both 